TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.

Claire Verschraegen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.